China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. has announced the extension and revision of their Sales Framework Agreement with CR Healthcare, which includes adjusting the annual caps for 2024 and 2025 and extending the agreement until the end of 2025. As CR Healthcare is a connected entity, holding 100% interest in the company, the agreement is subject to approval by independent shareholders at an upcoming Extraordinary General Meeting (EGM), with detailed information to be provided in a Circular by 31 July 2024.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
